{"id":"placebo-booster","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This appears to be an investigational approach by Arcturus Therapeutics to augment placebo response, potentially through improved formulation, delivery mechanism, or patient engagement strategies. The exact molecular or mechanistic basis is unclear from available public information. Placebo boosters are typically studied to understand contextual healing factors and optimize therapeutic outcomes in clinical settings.","oneSentence":"A placebo booster is a formulation designed to enhance the placebo effect through optimized delivery or presentation characteristics.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:26:43.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04235816","phase":"PHASE3","title":"Improving Care Through Azithromycin Research for Infants in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2021-03-15","conditions":"Child Mortality","enrollment":20560},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT05634876","phase":"PHASE1","title":"UB-312 in Patients With Synucleinopathies","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-05-31","conditions":"Multiple System Atrophy, Parkinson Disease","enrollment":8},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT06982820","phase":"NA","title":"Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia","status":"RECRUITING","sponsor":"GrayMatters Health Ltd.","startDate":"2025-06-25","conditions":"Depressive Disorder, Major","enrollment":170},{"nctId":"NCT05997264","phase":"PHASE2","title":"Anthrax AV7909 Boost Evaluation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2023-12-05","conditions":"Anthrax","enrollment":220},{"nctId":"NCT04704830","phase":"PHASE3","title":"R21/Matrix-M in African Children Against Clinical Malaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2021-04-29","conditions":"Malaria","enrollment":4800},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT04639466","phase":"PHASE1, PHASE2","title":"A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"GeoVax, Inc.","startDate":"2020-11-19","conditions":"COVID-19 Infection","enrollment":119},{"nctId":"NCT06889792","phase":"NA","title":"Prevent Non-communicable Diseases Through Screening and Educating Emergency Department Attendees to Adopt Healthy Lifestyles","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-06-10","conditions":"Non Communicable Diseases, Health-risk Behaviours","enrollment":1172},{"nctId":"NCT04588428","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2021-06-21","conditions":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","enrollment":192},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT03736538","phase":"PHASE1","title":"Nitrous Oxide- Suicidal Ideation","status":"ENROLLING_BY_INVITATION","sponsor":"Washington University School of Medicine","startDate":"2018-10-30","conditions":"Major Depressive Disorder, Depression, Mood Disorders","enrollment":50},{"nctId":"NCT06686654","phase":"PHASE1, PHASE2","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-11","conditions":"Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization","enrollment":1530},{"nctId":"NCT05643469","phase":"NA","title":"Self-determination Plus Instant Messaging for Smokers With Cancer","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-07-03","conditions":"Smoking, Cancer","enrollment":1448},{"nctId":"NCT06499012","phase":"NA","title":"The Efficacy of Nutrilite All-plant Protein Booster to Improve Sarcopenia and Osteoarthritis in Middle-aged and Elderly People","status":"COMPLETED","sponsor":"Amway (China) R&D Center","startDate":"2025-07-08","conditions":"Osteoarthritis, Sarcopenia","enrollment":139},{"nctId":"NCT02747927","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04-26","conditions":"Healthy Volunteers","enrollment":20099},{"nctId":"NCT05116241","phase":"PHASE2","title":"Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children","status":"COMPLETED","sponsor":"ILiAD Biotechnologies","startDate":"2021-11-11","conditions":"Bordetella Pertussis, Whooping Cough","enrollment":368},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT07209306","phase":"NA","title":"WHO Psychological Interventions for Mental Health Outcomes in Migrants Resettled in Italy: the ADVANCE Trial","status":"RECRUITING","sponsor":"Universita di Verona","startDate":"2025-04-09","conditions":"Distress, Psychological, Distress, Emotional","enrollment":237},{"nctId":"NCT05205746","phase":"PHASE2","title":"Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2021-11-23","conditions":"SARS CoV 2 Infection","enrollment":158},{"nctId":"NCT05477524","phase":"PHASE3","title":"An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-04","conditions":"Lyme Disease","enrollment":12547},{"nctId":"NCT07183696","phase":"NA","title":"Respiratory Muscle Training and Quality of Life in Hemodialysis Patients","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-10-01","conditions":"Hemodialysis","enrollment":50},{"nctId":"NCT04649151","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-12-09","conditions":"SARS-CoV-2","enrollment":4328},{"nctId":"NCT02134925","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-06-23","conditions":"Colorectal Adenoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Carcinoma","enrollment":110},{"nctId":"NCT07141472","phase":"NA","title":"Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study","status":"COMPLETED","sponsor":"Lawry Han","startDate":"2025-01-07","conditions":"Blood Sugar; High, Overweight and Obesity, Fat Loss","enrollment":69},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT03583606","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-11-12","conditions":"Ebola Disease, Immunisation","enrollment":61},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT03999996","phase":"PHASE3","title":"Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-11-12","conditions":"Dengue Fever","enrollment":365},{"nctId":"NCT06582277","phase":"PHASE2","title":"Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836","status":"COMPLETED","sponsor":"Osivax","startDate":"2024-10-22","conditions":"Vaccine-Preventable Diseases, Influenza","enrollment":117},{"nctId":"NCT05639894","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-17","conditions":"Respiratory Syncytial Virus Immunization","enrollment":865},{"nctId":"NCT03502707","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-06","conditions":"Healthy","enrollment":669},{"nctId":"NCT04228783","phase":"PHASE3","title":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-02-18","conditions":"Ebola","enrollment":974},{"nctId":"NCT04668339","phase":"PHASE2","title":"A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults","status":"TERMINATED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2021-01-07","conditions":"Covid19, SARS-CoV Infection, Corona Virus Infection","enrollment":581},{"nctId":"NCT05181709","phase":"PHASE1","title":"A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.","status":"COMPLETED","sponsor":"Sean Liu","startDate":"2022-02-09","conditions":"SARS-CoV-2","enrollment":35},{"nctId":"NCT06032000","phase":"PHASE1","title":"Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)","status":"COMPLETED","sponsor":"Lemonex","startDate":"2023-11-06","conditions":"COVID-19 Infection, COVID-19 Vaccine Adverse Reaction","enrollment":20},{"nctId":"NCT06007183","phase":"PHASE3","title":"Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2023-08-30","conditions":"Chikungunya Virus Infection","enrollment":800},{"nctId":"NCT05809271","phase":"PHASE1","title":"Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-11-17","conditions":"Healthy","enrollment":25},{"nctId":"NCT05312008","phase":"PHASE2","title":"Does Oxytocin Alter Tolerance to or Motivation for Alcohol","status":"TERMINATED","sponsor":"Indiana University","startDate":"2022-01-16","conditions":"Alcohol Use Disorder","enrollment":6},{"nctId":"NCT05007080","phase":"PHASE2","title":"A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-09-27","conditions":"Coronavirus Disease-2019 (COVID-19) Prevention","enrollment":304},{"nctId":"NCT04614948","phase":"PHASE3","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-11-12","conditions":"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19","enrollment":31835},{"nctId":"NCT04505722","phase":"PHASE3","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-09-07","conditions":"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol","enrollment":44325},{"nctId":"NCT04436276","phase":"PHASE1, PHASE2","title":"A Study of Ad26.COV2.S in Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-07-15","conditions":"Covid-19 Prevention","enrollment":1085},{"nctId":"NCT05819476","phase":"NA","title":"Boosting Open-Label Placebo Effects in Acute Induced Pain in Healthy Adults","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-23","conditions":"Acute Pain","enrollment":141},{"nctId":"NCT03068390","phase":"NA","title":"Rural Intervention for Caregivers' Heart Health","status":"COMPLETED","sponsor":"Debra Moser","startDate":"2017-02-24","conditions":"Cardiovascular Risk Factor","enrollment":311},{"nctId":"NCT05195151","phase":"NA","title":"Modification of the COVID-19 Vaccine Response by an Intervention on the Intestinal Flora","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2022-11-10","conditions":"COVID-19, Vaccine Reaction, Elderly","enrollment":592},{"nctId":"NCT02465268","phase":"PHASE2","title":"Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-08-09","conditions":"Glioblastoma Multiforme, Glioblastoma, Malignant Glioma","enrollment":175},{"nctId":"NCT06765824","phase":"PHASE3","title":"Transcranial Magnetic Stimulation in Patients with Dual Disorders","status":"NOT_YET_RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2025-02","conditions":"Major Depression, Tobacco Addiction","enrollment":36},{"nctId":"NCT05468736","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2022-07-22","conditions":"COVID-19","enrollment":3600},{"nctId":"NCT05693272","phase":"PHASE1","title":"A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2023-01-31","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 Infection","enrollment":47},{"nctId":"NCT05039853","phase":"NA","title":"Improving Mental Health Following Early PREgnancy Loss Using a Brief Cognitive Task","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2021-12-09","conditions":"Post-traumatic Stress Disorder, Miscarriage, Ectopic Pregnancy","enrollment":168},{"nctId":"NCT05178901","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Public Health Vaccines LLC","startDate":"2022-01-10","conditions":"Nipah Virus Infection","enrollment":60},{"nctId":"NCT04904549","phase":"PHASE3","title":"Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-20","conditions":"COVID-19","enrollment":23726},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05005247","phase":"PHASE1","title":"Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2021-08-17","conditions":"Group B Streptococcus Infection","enrollment":27},{"nctId":"NCT04319380","phase":"PHASE3","title":"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2020-04-01","conditions":"Malaria,Falciparum, Child, Only","enrollment":5098},{"nctId":"NCT06587503","phase":"PHASE4","title":"Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses","status":"NOT_YET_RECRUITING","sponsor":"University of Birmingham","startDate":"2024-10","conditions":"Ebola Virus Disease, COVID-19","enrollment":72},{"nctId":"NCT05397119","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2022-07-07","conditions":"Influenza, Pandemic","enrollment":40},{"nctId":"NCT04528719","phase":"PHASE1","title":"A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-09-30","conditions":"Respiratory Syncytial Virus","enrollment":651},{"nctId":"NCT05911061","phase":"PHASE3","title":"A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination","status":"NOT_YET_RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-12-30","conditions":"COVID-19","enrollment":4950},{"nctId":"NCT05576623","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine","status":"COMPLETED","sponsor":"Cellid Co., Ltd.","startDate":"2022-09-14","conditions":"COVID-19, Vaccines","enrollment":320},{"nctId":"NCT05163223","phase":"PHASE2","title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer","status":"TERMINATED","sponsor":"Aston Sci. Inc.","startDate":"2022-02-28","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT03911076","phase":"PHASE2","title":"Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL","status":"TERMINATED","sponsor":"PapiVax Biotech, Inc.","startDate":"2019-05-22","conditions":"ASC-US, ASC-H, LSIL","enrollment":16},{"nctId":"NCT00119067","phase":"PHASE4","title":"Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2002-05","conditions":"Healthy","enrollment":1564},{"nctId":"NCT05226702","phase":"PHASE1","title":"Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2022-07-22","conditions":"Double Vaccinated for COVID-19 (For Phase 1 of the Study), Acute Respiratory Syndrome Coronavirus 2 (For Phase 2 Exploratory Group)","enrollment":60},{"nctId":"NCT06175494","phase":"PHASE3","title":"A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)","status":"UNKNOWN","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2023-12-19","conditions":"COVID-19","enrollment":4800},{"nctId":"NCT05872360","phase":"NA","title":"To Investigate Effects of Amway Bundle Combination of Products on Osteoarthritis & Sarcopenia","status":"COMPLETED","sponsor":"Amway (China) R&D Center","startDate":"2023-05-27","conditions":"Osteoarthritis, Sarcopenia","enrollment":240},{"nctId":"NCT05685953","phase":"PHASE1","title":"A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Matti Sällberg","startDate":"2023-02-08","conditions":"COVID-19 Respiratory Infection, COVID-19 Vaccine Adverse Reaction","enrollment":16},{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT04470427","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-07-27","conditions":"SARS-CoV-2","enrollment":30415},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279},{"nctId":"NCT05383560","phase":"PHASE2","title":"Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection","enrollment":179},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06167915","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2023-12-26","conditions":"SARS-CoV-2, COVID-19 Vaccine","enrollment":120},{"nctId":"NCT05752201","phase":"PHASE2, PHASE3","title":"ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine","status":"COMPLETED","sponsor":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","startDate":"2023-02-06","conditions":"COVID-19 Vaccine","enrollment":2014},{"nctId":"NCT04611802","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-12-27","conditions":"SARS-CoV Infection, Covid19","enrollment":33000},{"nctId":"NCT04197687","phase":"PHASE2","title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","status":"UNKNOWN","sponsor":"Academic and Community Cancer Research United","startDate":"2020-02-20","conditions":"Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7","enrollment":480},{"nctId":"NCT04805879","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2021-03-04","conditions":"Depression, Treatment Resistant Depression","enrollment":80},{"nctId":"NCT05939648","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-10-09","conditions":"SARS-CoV-2","enrollment":450},{"nctId":"NCT05939596","phase":"PHASE1","title":"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-08-10","conditions":"SARS-CoV-2","enrollment":60},{"nctId":"NCT05873374","phase":"PHASE2","title":"Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19","status":"UNKNOWN","sponsor":"Baiya Phytopharm Co., Ltd.","startDate":"2023-12","conditions":"COVID-19 Vaccine, COVID-19","enrollment":75},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT05683600","phase":"PHASE3","title":"Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older","status":"TERMINATED","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-12-29","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT04502121","phase":"NA","title":"Preoperative Optimization of Cardiac Valve Patients' Expectations","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2020-07-17","conditions":"Cardiac Valve Disease","enrollment":89},{"nctId":"NCT05648773","phase":"NA","title":"COVID-19 Booster Incentives","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2022-12-08","conditions":"Booster Message, Booster Message + Financial Incentive","enrollment":57893},{"nctId":"NCT05422326","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-07-18","conditions":"Influenza, Human, Influenza in Birds, Respiratory Tract Infections","enrollment":260},{"nctId":"NCT05609045","phase":"PHASE1","title":"A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster","status":"WITHDRAWN","sponsor":"Wuhan Rhegen Biotechnology Co., Ltd.","startDate":"2023-06","conditions":"COVID-19 Pandemic","enrollment":""},{"nctId":"NCT04672395","phase":"PHASE2, PHASE3","title":"A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-03-24","conditions":"COVID-19","enrollment":31454},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT04510207","phase":"PHASE3","title":"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-07-16","conditions":"COVID-19","enrollment":44101},{"nctId":"NCT05272605","phase":"PHASE1","title":"Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2022-04-05","conditions":"SARS-CoV-2","enrollment":76},{"nctId":"NCT02107261","phase":"PHASE2","title":"Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-03","conditions":"Dystonia","enrollment":21},{"nctId":"NCT05366296","phase":"PHASE1","title":"Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine","status":"WITHDRAWN","sponsor":"Wuhan Recogen Biotechnology Co., Ltd.","startDate":"2022-07","conditions":"COVID-19 Pandemic","enrollment":""},{"nctId":"NCT05096832","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-03","conditions":"COVID-19 Pandemic","enrollment":10381},{"nctId":"NCT03970733","phase":"PHASE2","title":"Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-07-01","conditions":"Lyme Borreliosis","enrollment":246},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo booster","genericName":"Placebo booster","companyName":"Arcturus Therapeutics, Inc.","companyId":"arcturus-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}